Practice patterns in cervical cancer screening and human papillomavirus testing

American Journal of Clinical Pathology

Volumn 138, Issue 2, 2012, Pages 223-229

  Tatsas, Armanda D ^a   Phelan, Darcy F ^b   Gravitt, Patti E ^b   Boitnott, John K ^a   Clark, Douglas P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cotesting; HPV; Human papillomavirus; Papanicolaou test

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; FEMALE; HPV TEST; HUMAN; HUMAN EXPERIMENT; LABORATORY DIAGNOSIS; MICROBIOLOGICAL EXAMINATION; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREND STUDY; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MARYLAND; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PHYSICIAN'S PRACTICE PATTERNS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84865419970     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPPVX91HQMNYZZ     Document Type: Article

References (23)

1. Wright TC Jr., Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
2. Wright TC Jr., Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-355. (Pubitemid 47464164)
3. Wright TC Jr., Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
4. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819. (Pubitemid 46333946)
5. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588. (Pubitemid 47598400)
6. AGOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol. 2009;114:1409-1420.
7. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362. (Pubitemid 35446606)
8. Holland-Barkis P, Forjuoh SN, Couchman GR, et al. Primary care physicians' awareness and adherence to cervical cancer screening guidelines in Texas. Prev Med. 2006;42:140-145. (Pubitemid 43207422)
9. Saraiya M, Irwin KL, Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer. 2007;110:1024-1032. (Pubitemid 47312868)
10. Saraiya M, Berkowitz Z, Yabroff KR, et al. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med. 2010;170:977-985.
11. Yabroff KR, Saraiya M, Meissner HI, et al. Specialty differences in primary care physician reports of Papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med. 2009;151:602-611.
12. Phelan DF, Boitnott JK, Clark DP, et al. Trends of human papillomavirus testing in cervical cancer screening at a large academic cytology laboratory. Obstet Gynecol. 2011;118(2 Pt 1)289-295.
13. Shirts BH, Jackson BR. Informatics methods for laboratory evaluation of HPV ordering patterns with an example from a nationwide sample in the United States, 2003-2009. J Pathol Inform. 2010;1:26.
14. Moriarty AT, Schwartz MR, Eversole G, et al. Human papillomavirus testing and reporting rates: practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Gynecologic Cytology in 2006. Arch Pathol Lab Med. 2008;132:1290-1294.
15. Tworek JA, Jones BA, Raab S, et al. The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions. Arch Pathol Lab Med. 2007;131:1525-1531. (Pubitemid 47606718)
16. Thrall MJ, Russell DK, Facik MS, et al. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. Am J Clin Pathol. 2010;133:894-898.
17. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009;113:595-600.
18. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408-416. (Pubitemid 27384745)
19. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357:673-681. (Pubitemid 47267237)
20. Price RA, Frank RG, Cleary PD, et al. Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests. Med Care. 2011;49:132-138.
21. Lee JW, Berkowitz Z, Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 2011;118:4-13.
22. Colgan TJ. The 2006 consensus guidelines for the management of women with abnormal cervical screening tests: challenges remain. Cancer Cytopathol. 2010;118:233-237.
23. Austin RM, Onisko A, Druzdzel MJ. The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool. Arch Pathol Lab Med. 2010;134:744-750.